Exhibit 99.1

 ADMA Biologics  Realizing the Potential of Plasma-Derived Therapieswith Groundbreaking Immunotechnology  December 2021  NASDAQ: ADMA  

 Forward-Looking Statements    This presentation contains "forward-looking statements," pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. and its subsidiaries (collectively, “we,” “our” or the “Company”), including, without limitation, statements that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “potential,” “possible,” “forecast,” “intend,” “target,” “anticipate,” “plan,” “expect,” “believe,” “will,” “is likely,” “will likely,” “should,” “could,” “would,” “may” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements also include, without limitation, our plans to develop, manufacture, market, launch and expand our own commercial infrastructure and commercialize our current products and future products; our plans to expand our pipeline with differentiated immune globulin product candidates in development; potential near and mid-term value creation through certain milestones; the possibility of expanding our product portfolio with additional specialty immune globulin products; product expansions into new fields of use, indications, target populations and product candidates, and the labeling or nature of any such approvals; our dependence upon our third-party and related party customers and vendors and their compliance with regulatory bodies; our ability to obtain adequate quantities of U.S. Food and Drug Administration (“FDA”)-approved plasma with proper specifications; the likelihood and timing of FDA action with respect to any further filings by the Company; the expected financial, strategic and commercial benefits of the FDA’s approval of our VanRx SA25 Workcell aseptic fill finish machine; results of clinical development; the potential of specialty plasma-derived biologics to provide meaningful clinical improvement for patients living with Primary Immune Deficiency Disease (“PI”); expected market size growth in the U.S. immune globulin market through 2027; our ability to market and promote our products in the competitive environment and to generate meaningful revenues; our estimated revenue potential and related timing; certain revenue opportunities; our estimated revenue growth relative to our competitors; our production capacity and yield and ability to increase such capacity and yield; our ability to increase market share and grow revenue through anticipated product launches as well as expected peak market share; our ability to secure, build and obtain FDA approval for additional plasma collection centers and the timing related thereto; anticipated timing for achieving plasma supply self-sufficiency; estimated global supply and demand for plasma through 2027; the estimated value of our Boca Raton manufacturing facility; potential clinical trial initiations; potential investigational new product applications, Biologics License Applications, and expansion plans; our intellectual property position, including our expectations of the scope of patent protection with respect to our products or other future pipeline product candidates; the achievement of clinical and regulatory milestones; our manufacturing capabilities; third-party contractor capabilities and strategy; our plans relating to manufacturing, supply and other collaborative agreements; potential contract manufacturing opportunities and sales of our immune globulin products and intermediates; our estimates regarding expenses, capital requirements and needs for additional financing; possible or likely reimbursement levels for our currently marketed products and estimates regarding market size; projected growth and sales for our existing products as well as our expectations of market acceptance of BIVIGAM® and ASCENIV™; future economic conditions and performance; commercialization efforts relating to our products and the runway and limitation of our available cash; and our ability to identify alternative sources of cash. The forward-looking statements contained herein represent the Company’s estimates and assumptions only as of the date of this presentation, and the Company undertakes no duty or obligation to update or revise publicly any forward-looking statements contained in this presentation, except as otherwise required by the federal securities laws. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by these forward-looking statements, including, but not limited to, the continued safety and efficacy of, and our ability to obtain and maintain regulatory approvals of, our current products as well as our plans to increase our supplies of plasma; our ability to expand our plasma center network; regulatory processes and interpretations of final data of our products and product candidates; acceptability of any of our products for any purpose, by physicians, patients or payers; concurrence by the FDA with our conclusions and the satisfaction by us of its guidance the risks; and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto. 

 Who We Are   ADMA Biologics is an end-to-end commercial biopharmaceutical company committed to manufacturing, marketing and developing specialty plasma-derived products for the prevention and treatment of infectious diseases in the immune compromised and other patients at risk for infection   Our devotion to these underserved populations fuels us, and we believe our hands-on approach to production and development sets us apart   3 

   ADMA Investment Highlights  Differentiated U.S. Plasma Products Opportunity in a Large & Growing End-Market   1  Vertically Integrated with Leading Technology, Supply Chain & Production Processes  2  Well-Defined & Largely De-Risked Pathway to Profitability & Unique Scarcity Value  3  Potential Upside Through Operating Leverage & New Product Pipeline Opportunities   4 

     Differentiated Opportunity in a Large & Growing Market   One of six manufacturers in a historically undersupplied U.S. IG marketThe only fully vertically integrated U.S.-domiciled fractionator Four major producers (Grifols, CSL Behring, Shire and Octapharma) collectively account for >94% of U.S. IG marketExisting competitors are at or near capacity; ADMA is in early stages ofits growth and production ramp-up  ADMA is 1 of 6 Manufacturers in a Growing,Supply-Constrained U.S. Immunoglobulin (IG) Market  Comprehensive suite of three U.S. FDA-approved commercial IVIG products: Standard IVIG (BIVIGAM), including a range of vial sizes and configurations Hyperimmune IG portfolio, comprised of ASCENIV and Nabi-HBASCENIV is a novel IG and the only product in its class produced by blending normal plasma with hyperimmune plasma using ADMA’s patented methods Nabi-HB has been used for over 20 years to protect against hepatitis B infection among newly exposed individuals  ADMA Has Three FDA-Approved Products& Diversified Revenue Streams    ~$9.5Bn in 2020 Growing to $17Bn+ U.S. IG Market   Source: The Plasma Proteins Market In The United States 2020, Marketing Research Bureau Inc., July 2021  Six diversified revenue streams with the potential to add a seventh with third-party CMO fill-finish capabilities   1 

 Vertically Integrated with Leading Technology,Supply Chain & Production Processes  Contractually obligated third-party supply agreements expected to complement and bridge to plasma supply self-sufficiency by YE202310+ FDA-licensed plasma collection facilities anticipated to be fully FDA approved by YE2023Well-positioned infrastructure to support near term revenue growth and ensure continuity of product supply into the supply-constrained U.S. IG market   End-to-end control of supply chain from plasma collection through plasma fractionation, purification, fill-finish and testingAmong an elite group of U.S.-based biologic drug manufacturers with comprehensive in-house control of critical manufacturing and testing functions Operating in cGMP compliance with validated methodsSuccessful implementation of supply chain enhancements largely de-risks production scale-up and growth outlook   FDA approved In-house aseptic fill-finishing capabilities Ongoing exploration of potentially accretive third-party fill-finish opportunities VanRx anticipated to meet all internal production needs with additional idle capacity, potentially adding new third-party revenues   Plasma Supply Self-Sufficiency Anticipated by YE2023  End-to-End Control of Supply Chain  In-House Fill-Finish Functions   Manufacturing  Raw Material Collections  Filling & Packaging   Release & In-Process Testing         2 

   Well-Defined and De-Risked Pathway to Profitability& Unique Scarcity Value  Capital requirements, regulatory approvals and manufacturing lead time prohibit manufacturers from quickly increasing output and filling demand in end-market supplyUnique and complex manufacturing process with a long production cycle (7-12 months)Market demand forecasted to outpace industry supply for the foreseeable future   Strict regulatory requirements for plasma-derived therapeutics governed by the FDA and state health departmentsValidation, product registration and ultimate commercialization takes ~3 to 5+ years – all current and complete ADMA operates in cGMP compliance across its manufacturing footprint as per recent FDA inspections and approvals  ADMA estimates, based upon publicly disclosed fractionator transactions, Boca Plant valuation estimated at $400M+ and ~5 years to complete registrations, clinical trials and construction of a cGMP-compliant fractionation plant and fill-finish facility of equivalent capacity to ADMA’s  Complex Manufacturing Process Validated and U.S. FDA Approved  Adhere to Strict RegulatoryRequirements With Data,Compliant SOPs and Processes In-Place  Significant Scarcity Valuefor ADMA’s Plant  ADMA acquires the Boca Raton facility and all rights to BIVIGAM    JUNE2017  ADMA works diligently to bring manufacturing facility into FDA compliance  FDACompliance    JULY2018  ADMA successfully obtains FDA approval for the optimized manufacturing process for BIVIGAM    MAY2019      Source: Wall Street research  FDA Biologics inspection completed; achieved VAI compliance status     AUG2021    FDACompliance  3 

 Potential Upside Through Operating Leverage & New Product Pipeline Opportunities   Well-defined pathway to $300M+ revenues by 2025Fastest revenue growth profile forecasted within theplasma therapeutics landscape Potential capacity upside with modest capital investment requirements Expected to benefit from market share gains as well as end-marketIG growth  IP issued to screen hyperimmune donors, tailor compositionsand form plasma pools – IP protection through 2035Attractive label expansion opportunities for specialty IGs targeting patient populations with high unmet need; robust and growing IPestate to support exploration of additional indicationsPublished data supports potential evaluation of ASCENIV in immune-compromised patients infected with or at-risk for respiratory syncytial virus (RSV) infection and other respiratory viral pathogens in primary and secondary immune-deficient populations  Fractionation Facility Has 600,000 L Annual Plasma Processing Capacity, Supporting a ~$300M+ Revenue Opportunity  Robust and Growing IP Estate to Support Potentially Attractive New Product Opportunities   ADMA’s Patented Immunotechnology    Screen and identify high-titer RSV plasma donorsHyperimmune donors with sufficient antibodies to select pathogens are identified              Tailoredcompositions Tailored plasma poolsare derived from a unique blend of normal source plasma and plasma obtained from the selected donors                  Proprietarytesting A proprietary microneutralization assay quantitatively measures titer levels of neutralizing RSV antibodies in plasma donor samples        4 

   ADMA Offers a Multi-Faceted Revenue-Generation Platform          IG production and processing (including protein intermediates)   Source Plasma Supply  CMOActivities   ≥$300MAnnual RevenuePotential  Existing infrastructure supports manufacturing and commercial product opportunitiesto generate multiple meaningful sources of revenue collectively amounting to ≥$300M  Plasma protein intermediate paste sales to 3rd parties  Contract manufacturing and laboratory services; potentially additive 3rd party CMO revenue opportunities following 2021 Fill-Finish approval   ADMA BioCenters provides source plasma to 3rd parties  Three FDA-approved and marketed IG products; additional plasma-derived product candidates in development  


 Plasma Therapeutics  Introduction to Plasma-Derived Therapies and Immunoglobulins (IG)   ADMA’s optimized IG manufacturing process and validation for intermediate fractions allows for the potential to maximize revenue from each liter of plasma while producing life-sustaining and saving therapies  Plasma-derived therapeutics are essential,life-sustaining biologic drugs that replace absent proteins due to genetic and acquired disorders in hundreds of thousands of patients in the U.S. Many of these naturally occurring proteins are unable to be replaced by new, innovative therapiesMany patients require long-term treatments and some potentially for their entire life   Immunoglobulins (IG) or Intravenous Immune Globulins (IVIG) are pooled plasma-derived products from healthy plasma donors, containing a range of polyclonal antibodies against common pathogens (e.g., bacteria, fungi and viruses)Only 6 companies currently produce IVIG approved for the U.S. market, including CSL Behring, Grifols, Takeda, Octapharma, BPL and ADMAOther therapeutic products made from plasma proteins include: albumin, coagulation factors, alpha-1 and C-1 esterase, among others          45%Red and white Blood Cells and Platelets  55%Plasma  90%Water  7%Protein  3%Others  60%Albumin  15%IgG  24%Others  1%Factor VIII  Immunoglobulins (IG) 

   Plasma IG Market Is Sizeable & Growing  Current $9.5Bn US IG market expected to grow to $17.2Bn by 2027  Aging PopulationGeriatric population more susceptible to rare diseases treatable by IG products Global population of 65+ expected to nearly double by 2050Rise of Use of IGs in MedicineSurge in awareness related to treatment of rare diseases with IG productsWidening scope of indications treatable with IG productsImproved Diagnostics Improvements in diagnostics leading to increased rates of PI diagnosesCondition remains under-diagnosed; average PI diagnosis still takes 12.4 yearsIncreased Use of Immunosuppressive TherapeuticsIncreased utilization of immuno-oncology agents and other immunosuppressive therapeutics necessitating antibody supplementationIncrease in Number of Plasma Collection CentersGrowing number of plasma collection centers worldwideIncrease in public and private associations that spread awareness and information related to plasma collections  Drivers of IG Market Growth  Source: Marketing Research Bureau, 2020 U.S. Fractionation Market Report, ADMA internal analysis1. The Plasma Proteins Market In The United States 2020, Marketing Research Bureau Inc., July 20212. Others include Kedrion and BPL  $Bn  ADMA’s peak production capacity could garner a ~1.5-2.5% share of the market at scale  (2)  ~$9.5Bn US IG Market in2020 Set to Grow to $17Bn+(1)  Market Share of US IG Producers 

       In a 40 year study of 473 patients with PI on standard IVIG (3)  Potential Higher-Risk Target Populations (1)   Despite Decades of IG Use, Improved Therapies Still Needed  PI is a class of inherited genetic disorders that causes an individual to have a deficient or absent immune system due to either a lack of necessary antibodies or a failure of these antibodies to function properlyEstimated prevalence of 1:1,200 in the U.S., or approximately 250,000 peopleNIH estimates 500,000 undiagnosed PI patients in the U.S.Over 400 genetic defects are responsible for PIPatients typically receive monthly outpatient infusions of IVIG therapyWithout this exogenous antibody immune support, these patients would be susceptible to a wide variety of infectious diseases  ~10% Volume Growth Projected for IG to Treat PI (6)  Primary Immunodeficiency is a Significant Market Opportunity  Primary Immunodeficiency (PI) Overview (1)  Class  Est. Incidence (U.S.)  Est. Prevalence  Common variable immune deficiency (CVID)  1 in 25,000 to 1 in 50,000  2,000 to 5,000 patients  Severe combined immune deficiency (SCID) syndrome  ~100 new cases each year  500-1,000 patients on IVIG post-transplant  Wiskott-Aldrich syndrome (WAS)  ~4 in every 1,000,000 males  600 patients on IVIG therapy  DiGeorge syndrome (DGS)  1 in 4,000 births  1,000 patients on IVIG therapy  Ataxia telangiectasia (AT)  1 in 40,000 to 1 in 100,000  3,000 to 8,000 patients  X-linked hyper IgM deficiency (XHMD)  2 in every 1,000,000 males  350 patients on IVIG therapy  X-linked agammagobulinanemia (XLA)  1 in 10,000  3,500 patients more susceptible to viral infections  Source: ADMA information, on file, AAAAI, FDA, Product prescribing information, United Healthcare, Aetna, L.E.K. Consulting research and analysis  Despite standard IG therapy, patients continue to experience recurrent respiratory infection and chronic lung disease (2)(3)  90%  developed chroniclung disease (5)  developed bronchiectasis (5)  PI is a prevalent and under-diagnosed disorder long-treated with IG therapy,but a continual need for improved options remains  experienced recurrent respiratory tract infection (4)  29%  11%  2015 ‒ 2017 IG Volume Growth By Indication  2020 ‒ 2030 IG Volume Growth By Indication  1. Centers for Disease Control, National Institute of Health 2. The broad spectrum of lung diseases in primary antibody deficiencies. Eur Respir Rev. 2018.3. Morbidity and mortality in common variable immune deficiency over 4 decades. 4. The lung in primary immunodeficiencies: New concepts in infection and inflammation. Front Immunol. 2018.5. Subclinical infection and dosing in primary immunodeficiencies. Clin Exp Immunol. 2014.6. Wall Street research 

 IG is Widely Used and Reimbursed Across Payer Mix  FDA-approved use and evidence-based use is consistently expanding across therapeutic areas        FDA-Approved Uses*Primary immunodeficiency (PI)Multifocal motor neuropathyB-cell chronic lymphocytic leukemiaImmune thrombocytopenic purpuraKawasaki syndromeChronic inflammatory demyelinatingpolyneuropathy  Possible Additional Reimbursed Evidence-Based Uses  Acquired red cell aplasiaBone marrow transplantationDermatomyositisEnteroviral meningoencephalitisEstablished bacterial sepsisMultiple sclerosis  Multiple myelomaMyasthenia gravisNeonatal hemochromatosisParvovirus B19Pediatric HIVPost transfusion purpura  Rasmussen’s syndromeRenal transplant from liver donorSolid organ transplantationStaphylococcal toxic shockSystemic lupus erythematosusToxic epidemal necrolysis  *Source: ADMA information, on file, AAAAI, FDA, Product prescribing information, United Healthcare, Aetna, L.E.K. Consulting research and analysis. Not all uses approved for all IG products by FDA.  

   BIVIGAM® Overview  The Reintroduction of BIVIGAMRESULTS FROM ADMA’S STRONG EXECUTION AND REGULATORY EXPERTISE          IN A 1-YEAR STUDY OF PATIENTS WITH PI,BIVIGAM met all primary endpoints (1)(2)   * Target was 1 SBI / year; 99% CI of 0.136 SBI / patient/year; of 63 adult patients in the enrolled in the study, 58 were included in efficiency analysis PPPY= per patient per year.   Demonstrated protection from serious bacterial infections (SBIs) 0.037 rate of SBIs per year*During the 12-month study period, 2 serious acute bacterial infections occurred in 2 patients with an onset date between the first infusion of BIVIGAM and the first follow-up visit197 total infections in 58 patients were reported (3.7 infections PPPY)86% of patients were administered antibiotics (39.1 days PPPY)              Reduced health-related burdens Low rate of hospitalizations (0.21 days / PPPY)2 patients (3.4%) hospitalized for a total of 11 days (0.06%)Fewer missed days of school / work (2.3 days / PPPY)21 patients (36%) with total of 122 days (0.6%)        ADMA acquires Boca Raton manufacturing facility and all rights to BIVIGAM and Nabi-HB  June2017      ADMA works diligently to optimize production processes and bring the facility into FDA compliance; achieved VAI status  FDA Compliance  July2018  ADMA obtains FDA approval for manufacturing BIVIGAM; first commercial sales in August 2019      May2019  Ongoing reintroduction of BIVIGAM well-received in a high-demand IG market    Plasma-derived IVIG that contains a broad range of antibodies similar to those found in normal human plasmaIndicated for the treatment of patients with primary immunodeficiency (PI)ADMA received FDA approval for manufacturing BIVIGAM in May 2019 and recorded first commercial sale in August 2019  Approved and Reintroduced in May 2019by ADMA          Production of BIVIGAM is voluntarily suspended by previous owner due to manufacturing and compliance issues  Production Suspended  Dec2016  1. BIVIGAM Prescribing Information. Boca Raton, FL: ADMA Biologics; 20192. A new intravenous immunoglobulin (BIVIGAM) for primary humoral immunodeficiency. Expert Rev Clin Immunol. 2014.      FDA Biologics inspection completed; achieved VAI status   Aug2021      FDA Compliance  BIVIGAM: FDA-Approved Protection Against Serious Infections  Proven Efficacy in Treating Patients with PI  

   ASCENIVTM Overview  THE PRODUCTION OF ASCENIVONLY IVIG PRODUCT MANUFACTURED USING PATENTED DONOR SCREENINGAND PLASMA POOLING METHODS (1)  IN A 1-YEAR STUDY OF PATIENTS WITH PI,ASCENIV reported zero serious bacterial infections (SBIs)*   * SBIs were defined as a rate of <1.0 cases of bacterial pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, visceral abscess and bacterial meningitis per person-yearPPPY = per patient per year.  Patients and physicians can count on ASCENIV to reduce infection-related quality-of-life impactZero hospitalizations due to infectionOne patient from the study group was hospitalized because of a postoperative local wound infection from elective surgery<1 unscheduled medical visits PPPY24 out of 59 patients (41%) had a total of 54 unscheduled medical visits due to infections1.7 missed days of work / school / activity PPPY due to infection23 patients (39%) had a total of 93 missed days of work / school / activity due to infections out of a total of 21,535 patient days (<0.5%)32.9 days of antibiotic use PPPY37 patients (63%) used antibiotics due to infection (includes therapeutic use)    Potential additional target populations across patients at risk for RSV infection,including in organ transplants and chemotherapy    Novel IVIG with differentiation based on patented methods for donor selection and pooling process blending normal source and hyperimmune RSV plasma Indicated for the treatment of patients with primary immunodeficiency (PI)ADMA received FDA approval in April 2019 and recorded first commercial sale inOctober 2019  Approved and introducedin April 2019by ADMA  1. ADMA Biologics patents issued 9,107,906 – 9,714,283 – 9,815,886 2. ASCENIV Prescribing Information, ADMA Biologics, 2019  Plasma pool is derived from a minimum of 1,000 unique donors and blends normal source plasma with RSV plasma   Manufactured through a patented process using source plasma, which is acquired from donors screened using a microneutralization assay to detect and identify which donors possess naturally occurring neutralizing antibody titers to respiratory syncytial virus (RSV)  Plasma collected from U.S. FDA-licensed plasma collection centers   Meets potency requirements for 21CFR640                ASCENIV: FDA-Approved Protection Against Serious Infections  Proven Efficacy in Treating Patients with PI (2)      

   Nabi-HB® Overview  THE THREAT OF HEPATITIS B  NABI-HB PROVIDES PROTECTION AGAINST HEPATITIS B INFECTION WITHIN 24 HOURS OF ADMINISTRATION (7)  Anti-HBs = anti-hepatitis B surface antibodies; IU = international units; WHO = World Health Organization; HBIG = hepatitis immunoglobulin; HBV = hepatitis B virus; HIV=human immunodeficiency virus.  Highly protective potency with Nabi-HB (7)Each milliliter of Nabi-HB contains >312 IU/mL of anti-HBsThe potency of each milliliter of Nabi-HB exceeds the potency of anti-HBs in a U.S. reference hepatitis B immune globulinThe U.S. reference has been tested against the WHO standard and found to be equal to 208 IU/mL  Established brand and distribution channels driving increased utilization in PEP and sexual assault patients    Successfully used for over 20 years to protect against hepatitis B infection among newly exposed individuals (post-exposure prophylaxis PEP) Manufactured from plasma obtained from vaccinated donors with high titers of antibodies to hepatitis B surface antigen, anti-HBsReceived FDA approval in March 1999 under Nabi Biopharma; recorded first commercial sale under ADMA in April 2018  Approved in March 1999(via Nabi); marketed by ADMA beginning in June 2017  Delivers highly effective protection (7)Nabi-HB is 75% effective in preventing an HBV carrier state in those at risk following sexual exposure to persons with acute hepatitis BIf administered as a single dose within 2 weeks of exposure                                                  EFFICACY WHEN ADMINISATERED AS A SINGLE DOSE WITHIN 2 WEEKS OF EXPOSURE    75%  Effective  CDC Recommendations for Prophylaxis: Administering an HBIG with the HBV vaccine series is highly effective in preventing transmission following exposure to HBV (1)          The HBV vaccine series alone takes up to 2 weeks to achieve initial serum levels and 3 doses (across 6 months) to provide seroprotection in ~90% of patients (1)(5)(6)Waning antibody levels may compromise seroprotection over timeAmong immunocompetent HBV vaccine responders, protection lasts 15 to 20 years (1)~67% of U.S. adults 19-49 years old do not have adequate HBV vaccination coverage (1)  HBV is 50-100x more infectious than HIV (1)The risk of blood-borne infections being transmitted after a sexual assault is greater than with consensual sex (1)(2)Incidence of HBV exposure during sexual assault is unknown since the HBV status of perpetrators is rarely known (3)Once someone is exposed to HBV, it may take hold and develop into potentially deadly chronic liver disease (4)  Poses An Immediate Threat to Sexual Assault Patients  Seroprotection Remains a Serious Issue  Nabi-HB: FDA-Approved for Enhanced Immunity Against Hepatitis-B   Proven Efficacy in Treating Hepatitis B  1. Centers for Disease Control and Prevention.2. Middlesex-London Health Unit. Post exposure management: hepatitis B, hepatitis C and HIV3. Roberts and Hedges' Clinical Procedures in Emergency Medicine and Acute Care4. World Health Organization5. Do patients who received only two doses of hepatitis B vaccine need a booster? Cleve Clin J Med. 20146. PDR: prescriber’s digital reference. Engerix (hepatitis B vaccine recombinant) drug summary7. Data on file. ADMA Biologics 

   ADMA’s Patented Immunotechnology is Used to Manufacture ASCENIV™              PATENTS ISSUED9,107,906 - Composition9,714,283 - Use9,815,886 - MethodsExpiration 2035  *These patents include the use of IG for treatment and prevention of all viral induced respiratory infections     18 

   Pipeline & Label Expansion Opportunities   Published data suggests additional label expansion opportunities may be explored for ASCENIV™   Potential additional target populations for ASCENIV™   As previously disclosed, we believe the published data and FDA approval of ASCENIV™ better positionsADMA to further its mission to evaluate ASCENIV™ in immune-compromised patients infected with or at-risk for Respiratory Syncytial Virus (RSV) infection     HSCT/Bone Marrow Transplant ~22,000 procedures/year performed in the USSolid Organ Transplant (lung, heart, liver and multi-organ) ~14,000 solid organ transplants/year (excluding kidney transplants) performed in the USCancer Patients Receiving Chemotherapy ~650,000 patients/year receive chemotherapy in the USOthers At-Risk for RSV Infection 

         Commercialization/Distribution Strategyfor ADMA’s Immunoglobulins  Identified and engaged with appropriate channel partners that align with our call planand sites-of-service where there is demand across our immunoglobulin portfolio  Distribution channel is well definedInpatients – hospital basedOutpatients – infusion center / physician office / homecare  Well established distribution organizations handle cold-chain products efficientlyHave existing product serialization tracking systemsHave existing relationships with hospital pharmacy buyers and infusion center/homecare purchasing departments  ADMA’s product portfolio offerings have overlapping prescriber call pointsClinical immunologistsInfectious diseasesHematology/oncologyCritical care & emergency medicine  HOSPITALPHARMACY  TIER ONE INSTITUTIONS  INDEPENDENTINFUSION CENTERSHOME CARE COMPANIESINDEPENDENT GPOs                                  EMERGENCY MEDICINE  INFECTIOUS DISEASE  CLINICAL IMMUNOLOGY  HEMATOLOGY/ONCOLOGY 

   Plasma Product Manufacturing Overview 

   Fractionation plants are scarce with only a few companies operating FDA-approved facilities in the U.S.  World-class, cGMP-compliant plasma fractionation facility and laboratories in Boca Raton, FL; acquired in June 2017 Recent FDA compliance inspection completed in August 2021 One of few FDA-approved fractionation facilities in the U.S.Total staff: ~350Annual capacity of up to 600,000 liters, or ~2.4M grams of finished IG, supporting a $300M+ revenue opportunityYield of ~3.5-4 g / L and revenue / liter of $600-$800Patented immunotechnology to screen hyperimmune donors, tailor plasma pool compositions and conduct proprietary antibody detection testingCapable of full product transfers as well as initial phase plasma product concept development In-house fill-finish capabilities following the 2021 FDA approval of the VanRx machine Plasma Intermediates are harvested with each batch of IG produced (e.g., Cryoprecipitate and Fraction V). Potential for up to $20M annual revenue opportunity  ADMA ManufacturingOne of Few Manufacturers of Specialty IGs in the U.S. 

 Production of Plasma-Derived Therapies  Approximately 4-6 months – includes all in-process bulk testing and batch record reviewand release by ADMA and any 3rd parties     Cohn-Oncley Cold Ethanol Fractionation Process (Estimated 7-12 Months)     End-to-end control of the supply chain and production process to produce our productsand leverage our expertise as a CMO for others       Donors  Plasmapheresis  Source plasma for manufacturing   Must include a 45 day hold per FDA regulation     Raw MaterialCollections  1      Manufacturing  Cryoprecipitate  Viral inactivation   II+III Paste / IG / IVIG  Fraction IV  Fraction V  Fractionation (upstream)  Purification (downstream)  Ultra-filtration   Final formulation   2    Filling & Packaging  Filling into vials   Final packaging & labeling  Lot # serialization   3    Release & In-Process Testing  ADMAin-house   3rd party labs  FDA review of each lot  90 days for certain 3rd party lab release tests    4     

 Internal fill-finish production capabilities expected to result in:                Product Labeling, Packaging and Serialization  New VanRx SA25 aseptic fill-finish machine received FDA approval  In-house fill-finish capabilities with the 2021 FDA approval of the VanRx SA25 workcell In-house specialty team to oversee third-party operationsPotential to improve final product yield and enhance margins, speed and time to release product to market   Greater product supply consistency  Significantly improved operational efficiencies            Significantlyimproved gross margins      Contract Manufacturing Opportunities: Fill-Finish, Packaging and Serialization   Reducedmanufacturing cycle times              Fill-Finish Capabilities  VanRx Machine Brings Fill-Finish Capabilities In-House  

   Plasma Collection Centers: 

 ADMA BioCenters Overview:Advancing Towards Plasma Self-Sufficiency   Plasma collection centers are essential to ensure raw material supply to produce IG and other plasma proteinsADMA BioCenters currently consists of a network of9 plasma collection centers in various stages of approval and developmentTotal staff: ~150First center opened in 2011; network now includes 6 fully operational BioCenters in Tennessee, South Carolinaand GeorgiaOn track to have 10+ FDA approved centers by 2023 to achieve substantial plasma supply self-sufficiencyADMA BioCenters collects hyperimmune and normalsource plasmaIn addition to providing plasma supply for ADMA products, collected plasma is sold through supply contracts to leading plasma companies  Plasma centers are essential to ensure raw material supply to produce IG and other plasma proteins;Supply self-sufficiency forecasted to be achieved by 2023  

     Expanding the ADMA BioCenter Network - 2021 Forward   Enhance economies of scale, speed to market, self-reliance, and increase market share   FDA-approved validation, SOPs, and training documentation in place  Opening additional centers – low regulatory risk and rapid time to first collections due to current FDA approval of documentation and methods  Plan to have 10 or more collection centers in approved in various geographic locations across the US by 2023  Vertical integration provides ADMA with increased speed to ramp to peak collection volumes in FDA-approved biologics manufacturing plants  Use what we need, sell what we don’t – decrease COGS, and generate additional revenue  Goals  Realize forecasted economies of scale as collections increase reducing the overall cost per L   Enhance efficiencies and ensure self-sufficiency into the future   Growth of the ADMA plasma collection network to firm up the ability to ramp IG production and grow market share  

   Milestones, Corporate and Financial Highlights   

 Experienced Management Team and Board of Directors      NAME  SELECTED CURRENT OR PAST AFFILIATIONS  Adam GrossmanFounder, President, CEO & Director  Brian Lenz, CPAExecutive Vice President, Chief Financial Officer  Dr. Jerrold GrossmanFounder & Vice Chairman  Lawrence GuiheenDirector  Martha DemskiDirector  Bryant FongDirector  Steven ElmsChairman  Young Kwon, Ph.D.Director 

 Financials  Current Financial Overview  Nine Months Ended September 30, 2021   Nine Months Ended September 30, 2020  Revenues  $54.6M  $28.3M  Net Loss  $(55.0M)  $(56.3M)  Loss per common share  $(0.44)  $(0.68)  Cash and cash equivalents  $34.4M  $59.7M  Total assets   $238.7M  $190.0M  Total liabilities  $135.9M  $118.6M  Total stockholders' equity  $102.8M  $71.4M  Common stock outstanding  195.8M  94.5M  Fully diluted common stock outstanding  212.6M  103.9M  Cash Balance Excludes Gross Proceeds of $57.5M From Equity Financing Completed October 2021 

   Upcoming Milestones  OBJECTIVES  Execute on supply chain robustness for increased BIVIGAM® plasma pool scale  Execute on supply chain robustness for aseptic fill/finish machine  Expand our BioCenters plasma collection facility network to a total of 10 or more  Expand commercial production and penetration of our marketed IVIG product portfolio  Disclose potential product development pipeline consisting of additional specialty plasma and/or hyperimmune IG products 

   ADMA Investment Highlights  Unique and Different Supply-Chain Nuances and Regulatory Requirements  Long production cycle-time – it can take 7 to 12 months for the end-to-end production, fill/finish, testing and release of a batch of IG  Large inventories required for raw material and in-process product are needed to ensure consistent and routine supply Raw material US source plasma is in high demand globally with commodity-like pricing  To market plasma products for the US, products must be made from US donor plasma in FDA-approved biologics manufacturing plants  Regulatory Barriers – Strict rules and regulations from FDA and State health departments; FDA performs release testing for each batch of ADMA’s IG products  Working capital requirements are substantial due to product production cycle and sales receivable cycle   Commercial Sales & Production Ramp Underway  ADMA manufactures and markets 3 FDA-approved IG products in the US:BIVIGAM® relaunched and marketed in 2019ASCENIV™ first commercial sales in 2019NABI-HB® marketed in the US since 1999  Potential peak revenues of all ADMA’s IG products and production processes to reach >$300M as we ramp production  ADMA controls all aspects of manufacturing, regulatory affairs and quality assurance  Opportunities to expand production capacity, increase production yield and revenue while enhancing margins  Patent portfolio across hyperimmune IG landscape including the production of ASCENIV™   ADMA Biologics has existing infrastructure and processes in place to manageplasma-derived products distinctive requirements  32 

   Thank You